SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Cost-effectiveness of direct acting oral anticoagulants in the prevention of thromboembolic complications: limits and concerns of economic evaluations.

Russo, P; Rosano, GMC; Favato, G; Staniscia, T; Romano, F (2019) Cost-effectiveness of direct acting oral anticoagulants in the prevention of thromboembolic complications: limits and concerns of economic evaluations. J Cardiovasc Med (Hagerstown), 20 (8). pp. 500-503. ISSN 1558-2035 https://doi.org/10.2459/JCM.0000000000000805
SGUL Authors: Rosano, Giuseppe Massimo Claudio

[img]
Preview
PDF Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (756kB) | Preview

Abstract

Economic evaluations have a widespread application in many areas of clinical research and play a key role in the clinical decision-making process. However, economic analyses have been sometimes used to produce new 'evidence' that is not adequately tested in the target population. This is the case of data arising from a systematic review of clinical trials evaluating the use of direct acting oral anticoagulants for the prevention of stroke in patients with atrial fibrillation. Taking into account this example, here we discuss the concerns raised by the improper interpretation of the results. Our conclusions are three-fold. Data from economic analyses should not be shifted to a clinical recommendation. Simulation models should not be used to generate new 'evidence' that is not supported by experimental data and is misleading. Clinical judgment is therefore pivotal to interpret results emerging from economic analyses.

Item Type: Article
Additional Information: This is a non-final version of an article published in final form in Russo, P; Rosano, GMC; Favato, G; Staniscia, T; Romano, F (2019) Cost-effectiveness of direct acting oral anticoagulants in the prevention of thromboembolic complications: limits and concerns of economic evaluations. J Cardiovasc Med (Hagerstown), 20 (8). pp. 500-503.
Keywords: Cardiovascular System & Hematology
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: J Cardiovasc Med (Hagerstown)
ISSN: 1558-2035
Language: eng
Dates:
DateEvent
August 2019Published
25 April 2019Published Online
25 March 2019Accepted
Publisher License: Publisher's own licence
PubMed ID: 31033777
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/111403
Publisher's version: https://doi.org/10.2459/JCM.0000000000000805

Actions (login required)

Edit Item Edit Item